Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.39 |
| ▸ | LTA4H | P09960 | 3/20 | 0.37 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150523 | 0.87 | LTA4H (0.38) | HDAC1LTA4HPYCR1 | |
| SCHEMBL4173616 | 0.86 | PRMT6 (0.42) | KDM4AKDM4CHDAC1 | |
| SCHEMBL3670575 | 0.84 | LTA4H (0.38) | LTA4HPYCR1 | |
| SCHEMBL3672635 | 0.82 | SIGMAR1 (0.36) | HDAC1LTA4HPYCR1 | |
| SCHEMBL4165962 | 0.81 | ALDH1A1 (0.33) | PYCR1 | |
| SCHEMBL27808224 | 0.80 | FFAR1 (0.56) | — | |
| SCHEMBL3668815 | 0.78 | HRH3 (0.57) | PYCR1TSHR | |
| SCHEMBL3662196 | 0.77 | S1PR1 (0.44) | HDAC1 | |
| SCHEMBL4158865 | 0.77 | ABCC4 (0.53) | TSHR | |
| SCHEMBL3668234 | 0.76 | FFAR1 (0.37) | KDM4CHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101970435-B | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG | 2014-07-02 | — | — | CN | claimed |
| CN-101970435-A | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG | 2011-02-09 | — | — | CN | claimed |
| EP-2242756-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | Novartis AG (CH) | 2010-10-27 | — | — | EP | claimed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | claimed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | KDM4A 210/4885KDM4C 419/4885HDAC1 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.